Sarepta ($SRPT) Faces Backlash for Censoring Critical Duchenne Advocacy Video

Jul 29, 2024, 12:18 PM

Sarepta Therapeutics ($SRPT) has come under scrutiny for demanding a prominent Duchenne muscular dystrophy patient advocacy organization censor a video that contained pointed criticism of its new gene therapy. The video, which was critical of Sarepta's approach and its impact on patients, was subsequently taken down. This incident, reported by STAT, has raised questions about the relationship between drugmakers and patient advocacy groups. The news has sparked discussions about the influence pharmaceutical companies exert over advocacy organizations and the potential implications for patient care and transparency.